Concentration‐QTc modeling of sitravatinib in patients with advanced solid malignancies
Sign Up to like & getrecommendations! Published in 2024 at "Clinical and Translational Science"
DOI: 10.1111/cts.13808
Abstract: Sitravatinib (MGCD516) is an orally available, small molecule, tyrosine kinase inhibitor that has been evaluated in patients with advanced solid tumors. Concentration‐corrected QT interval (QTc; C‐QTc) modeling was undertaken, using 767 matched concentration‐ECG observations from… read more here.
Keywords: qtc modeling; solid malignancies; patients advanced; concentration ... See more keywords